Biology and Therapeutic Targeting of Malignant Monocytes in Myeloid Blood Cancers
Abstract
This project is focused on the FY20 PRCRP topic area of blood cancers. This project addresses several Military Health Focus Areas, including: (i) environmental / exposure risk factors associated with blood cancer development (Aim 1), (ii) gaps in blood cancer prevention, early detection/diagnosis, prognosis and treatment (Aims 1, 2, 3). There is a fundamental gap in understanding the role of clonal monocytes in the pathogenesis and progression of myeloid blood cancers. Continued existence of this gap represents an important problem because despite the poor prognosis of myeloid blood cancers characterized by malignant monocytosis, there are currently no treatment strategies to effectively target monocytes in patients with myeloid malignancies. The central hypothesis of this project is that clonal monocytes have cell-intrinsic abnormalities that result in the development of aberrant inflammatory responses to common stimuli (e.g. infection), which drives the pathogenesis and progression of myeloid blood cancers. The overall objectives are to determine the molecular consequences of inflammation in clonal monocytes, to understand how this contributes to the pathogenesis and progression of myeloid blood cancers and to use this information to develop novel therapeutic approaches to target malignant monocytes in patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1221792
Entities
People
- Ann Mullally
Organizations
- Brigham and Women's Hospital